Login to Your Account



Clinic Roundup


Wednesday, January 11, 2012
• Immuron Ltd., of Melbourne, Australia, said the FDA cleared its investigational new drug application to begin a Phase IIb trial of bovine colostrum-derived Imm124-E for nonalcoholic steatohepatitis – a chronic inflammatory disorder of the liver – and fatty liver disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription